Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
December 2013—Myriad Genetics launched a new prognostic test, Myriad myPlan Lung Cancer, for patients diagnosed with early stage lung adenocarcinoma. MyPlan Lung Cancer is an RNA expression panel of 31 cell-cycle-progression genes in combination with tumor staging information to determine a patient’s risk of dying from lung cancer within five years.
December 2013—Microbiologics, a St. Cloud, Minn.-based company, has acquired Phthisis Diagnostics. Phthisis’ innovative, patented G-Sphere molecular standards product line will be the foundation for Microbiologics’ move into molecular products and a new division it is forming. G-Sphere standards are synthetic genes that provide controls for virtually any organism or molecular assay.
December 2013—Illumina announced the launch of its TruGenome Undiagnosed Disease Test provided by the CLIA-certified, CAP-accredited Illumina Clinical Services Laboratory. This new service uses whole genome sequencing to assist physicians in identifying the underlying genetic cause of a rare or undiagnosed disease.
December 2013—Bio SB, a molecular pathology company based in Santa Barbara, Calif., announced the launch of its Bcl-6 rabbit monoclonal antibody for in vitro diagnostic use. Bcl-6 is a transcriptional regulator gene that codes for a 706-amino-acid nuclear zinc finger protein.
The Legato 110 DRS (dual-rate syringe) pump system offers researchers complete flexibility to start two pumps simultaneously for delivery of two independent flow rates.
Leica Biosystems has signed an agreement to supply HealthTrust, a group purchasing organization and provider of total cost management solutions for health care facilities, with its broad range of histology instrumentation, laboratory consumables, and sample-tracking systems.
TriLink BioTechnologies, a provider of custom nucleic acid-based products, announced the launch of MitoPrimers, dilute-and-go primers for mitochondrial DNA PCR amplification and sequencing in forensic identification. The high sensitivity of mtDNA PCR amplification and sequencing allows forensic scientists to obtain information from evidence associated with homicides or other criminal investigations, body identifications, and cold cases, as well as small pieces of evidence containing little biological material.
Bio SB, a molecular pathology company based in Santa Barbara, Calif., has announced that it will partner with Cancer Diagnostics Inc. to distribute the Bio SB line of IHC antibodies, chromogens, and ancillaries in the U.S. market.
Biosearch Technologies, a supplier of oligonucleotide components to the rapidly growing molecular diagnostics industry, announced that it has acquired worldwide rights to TurboFISH technology, a method for rapid single molecule RNA FISH. With the TurboFISH license, Biosearch maintains exclusive access to continuing Stellaris RNA FISH-based inventions from Rutgers, The State University of New Jersey.
Ventana Medical Systems announced the global launch of its BRAF V600E immunohistochemistry test to detect the BRAF V600E mutation in a variety of tumors. The test, launched as a U.S. class I exempt/CE-IVD product, is designed to detect the most frequent BRAF mutation, V600E, which has been found to play a key role in a variety of cancers, including colorectal cancer.
